What's Happening?
NeoGenomics, a leading cancer diagnostics company, is set to present new data at the 2025 San Antonio Breast Cancer Symposium (SABCS) regarding its RaDaR 1.0 assay. This assay is used for detecting molecular residual disease (MRD) in early breast cancer.
The data comes from the SURVIVE HERoes Phase III trial and the CLEVER study, both of which utilized RaDaR 1.0 circulating tumor DNA (ctDNA) testing. These findings highlight the growing importance of ctDNA approaches in early breast cancer research and recurrence monitoring. NeoGenomics, headquartered in Fort Myers, Florida, operates a network of CAP-accredited laboratories and offers a comprehensive oncology-focused testing menu.
Why It's Important?
The presentation of NeoGenomics' ctDNA research at SABCS 2025 is significant as it underscores the potential of tumor-informed ctDNA approaches in improving cancer diagnostics and treatment. By providing actionable information to care teams, these methods can enhance patient monitoring post-treatment, potentially leading to earlier detection of cancer recurrence and improved survival rates. This advancement could influence the standard of care in oncology, benefiting oncologists, pathologists, and patients by integrating MRD insights into routine cancer care.
What's Next?
The continued development and validation of ctDNA testing methods like RaDaR 1.0 could lead to broader adoption in clinical settings. As NeoGenomics builds evidence for integrating MRD insights into oncology care, the company may seek regulatory approvals and partnerships to expand the use of its diagnostic tools. This could result in more personalized and effective cancer treatment strategies, ultimately improving patient outcomes.
